Nov 29, 2023
Dr. Jim Woody, CEO and Director of 180 Life Sciences, discusses the company's vision for safer pain and inflammation management. Their earlier work on anti-TNF therapy revolutionized the treatment of conditions such as rheumatoid arthritis. Now 180 Life Sciences focuses on additional indications of inflammation,...
Nov 29, 2023
Dr. Jim Woody, CEO and Director of 180 Life Sciences, discusses the company's vision for safer pain and inflammation management. Their earlier work on anti-TNF therapy revolutionized the treatment of conditions such as rheumatoid arthritis. Now 180 Life Sciences focuses on additional indications of inflammation,...
Oct 18, 2023
Anthony Mack, CEO of Virpax Pharma, is developing non-addictive pain drugs focusing on repurposing existing molecules and improving the delivery platform to enhance bioavailability and sustained delivery. With an initial focus on postoperative pain management and preventing opioid tolerance, their product, Probudur, is...
Oct 18, 2023
Anthony Mack, CEO of Virpax Pharma, is developing non-addictive pain drugs focusing on repurposing existing molecules and improving the delivery platform to enhance bioavailability and sustained delivery. With an initial focus on postoperative pain management and preventing opioid tolerance, their product, Probudur, is...
Jul 11, 2023
John Mulcahy, President and CEO of SiteOne Therapeutics, is developing new therapies to treat hypersensitivity disorders. Their approach focuses on targeting specific voltage-gated sodium channels. Their drug candidates are designed to treat acute pain, as well as hypersensitivity developed as a result of chronic...